Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Han Yong Choi
ERCC1 as a Biomarker for Bladder Cancer Patients Likely to Benefit From Adjuvant Chemotherapy
BMC Cancer
Cancer Research
Oncology
Genetics
Related publications
Mp58-07 Use of Adjuvant Chemotherapy in Patients With Advanced Bladder Cancer After Neoadjuvant Chemotherapy
Journal of Urology
Urology
Adjuvant Chemotherapy Versus Observation After Radical Cystectomy in Patients With Node-Positive Bladder Cancer
Scientific Reports
Multidisciplinary
P1.16-12 Identification of a Biomarker Panel in Resected NSCLC That Predicts Patient Outcomes and Benefit From Adjuvant Chemotherapy
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Correlations Between Microsatellite Instability, ERCC1/XRCC1 Polymorphism and Clinical Characteristics, and FOLFOX Adjuvant Chemotherapy Effect of Colorectal Cancer Patients
Cancer genetics
Cancer Research
Genetics
Molecular Biology
Pd15-09 Neoadjuvant vs Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Propensity Matched Analysis
Journal of Urology
Urology
Mismatch Repair Status in the Prediction of Benefit From Adjuvant Fluorouracil Chemotherapy in Colorectal Cancer
Gut
Gastroenterology
Correlation of ERCC1 Expression in Peripheral Blood Lymphocytes With Outcomes of Patients With Gastric Cancer Treated With Oxaliplatin-Based Adjuvant Chemotherapy
Genetics and Molecular Research
Medicine
Genetics
Molecular Biology
Role of Progranulin Gene Expression as a Molecular Biomarker for Bladder Cancer
American Journal of Biochemistry and Biotechnology
Biochemistry
Biotechnology
A Novel Biomarker for Diagnosis of Bladder Cancer
Folia Pharmacologica Japonica
Pharmacology